Drugs / fluticasone propionate/salmeterol
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02680561 | Apr → Jun 2016 | asthma | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2016-06-28 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces FDA Acceptance of New Drug Applications for Fluticasone Propionate/Salmeterol and Fluticasone Propionate RespiClick® Inhalers tevapharm.com ↗ |
| 2015-11-19 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Reports Positive Top-Line Results from Phase III Trials Evaluating Fluticasone Propionate/Salmeterol and Fluticasone Propionate Multidose Dry Powder Inhalers (MDPIs) in Patients with Asthma tevapharm.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | fluticasone propionate/salmeterol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02680561 ↗ |
| Route | Inhaled | “single oral inhalation dose” NCT02680561 ↗ |